Want to see SE:BINV full AI Analyst Report?
Top Page
BioInvent International AB
(BINV)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr20.00
▼(-14.89% Downside)
Action:Reiterated
Date:08/28/26
The score is primarily held down by weak financial performance—steep TTM revenue decline, large operating losses, and significant ongoing cash burn—raising funding dependence risk. Technicals add downside pressure with the stock trading below all key moving averages and only modest momentum signals. Valuation provides little support due to a negative P/E and no dividend yield data.
Positive Factors
Proprietary oncology platform
The proprietary discovery platform and specialized immune-oncology expertise provide a foundation for generating differentiated antibody candidates. This can support repeated pipeline creation, partnering opportunities, and strategic relevance with larger pharmaceutical companies over the next several quarters.
Negative Factors
Severe revenue contraction
The steep TTM revenue decline shows that current income generation is not stable, which is significant for a clinical-stage company reliant on collaborations and milestone-related inflows. Sustained weakness would limit internal funding capacity and increase dependence on future deals or financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oncology platform
The proprietary discovery platform and specialized immune-oncology expertise provide a foundation for generating differentiated antibody candidates. This can support repeated pipeline creation, partnering opportunities, and strategic relevance with larger pharmaceutical companies over the next several quarters.
Read all positive factors
BioInvent International AB (BINV) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.53B
Dividend YieldN/A
Average Volume (3M)79.35K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth-87.22%
EPS Growth-70.29%
CountrySE
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.55
Shares Outstanding65,804,360
10 Day Avg. Volume67,092
30 Day Avg. Volume79,348
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.36
Revenue Forecast (FY)kr49.24M
BioInvent International AB Business Overview & Revenue Model
Company Description
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. It...
How the Company Makes Money
BioInvent makes money primarily through (1) collaboration and licensing arrangements and (2) potential product commercialization, supplemented at times by other operating income typical for clinical-stage biotech companies.
1) Collaboration and l...
BioInvent International AB Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.Positive Updates
Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)
Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.
Negative Updates
Sharp Q4 2025 net sales decline
Q4 2025 net sales SEK 3.0 million vs SEK 21.4 million in Q4 2024 — a decrease of SEK 18.4 million (~-86%), primarily due to lower production revenues for antibodies for customers.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)
Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.
Read all positive updates
Company Guidance
The management outlined a dense near‑term catalyst calendar and clear go/no‑go signals: clinical readouts are expected mid‑2026 (first Phase IIa BI‑1808+pembro in CTCL; additional BI‑1206 triplet NHL data) and in 2H‑2026 (further BI‑1808+pembro solid‑tumor data and first readout from BI‑1206+pembro in first‑line NSCLC and uveal melanoma), with concrete 2027 inflection points including completion of BI‑1808 monotherapy dose optimization in 1H‑2027 and potential pivotal starts (BI‑1808 pivotal in 2H‑2027; BI‑1206 NHL pivotal potentially 1H‑2027; BI‑1206 Phase IIb in NSCLC possibly 2H‑2027). Key clinical metrics already reported: BI‑1808 ovarian combo ORR 24% and disease control rate 57% (21 ovarian patients available), BI‑1808 CTCL monotherapy 46% ORR and 92% disease control in 13 evaluable CTCL patients (including a CR >1 year), BI‑1206 triplet in NHL ~80% ORR and 100% disease control (activity across follicular, marginal zone and mantle cell; current cohort ~30 patients), and a target benchmark of ~60% ORR for BI‑1206 in first‑line NSCLC to consider advancement. Financially, Q4‑2025 net sales were SEK 3m (vs SEK 21.4m a year earlier), full‑year net sales SEK 226m (vs SEK 45m), Q4 operating costs SEK 132m (Q4‑2024 SEK 147m), full‑year operating costs SEK 578m (2024 SEK 516m), Q4 result −SEK 125.8m and full‑year result −SEK 332.9m, with liquid funds/current investments of SEK 593m and the company assessed as financed for the coming 12 months.BioInvent International AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.51M | 226.50M | 44.69M | 71.46M | 326.13M | 19.38M |
| Gross Profit | 29.19M | 226.50M | 44.69M | 71.46M | 326.13M | 19.38M |
| EBITDA | -486.51M | -331.52M | -409.38M | -312.71M | -27.13M | -263.32M |
| Net Income | -497.16M | -332.86M | -429.38M | -330.30M | -34.09M | -278.96M |
Balance Sheet | ||||||
| Total Assets | 423.94M | 671.20M | 989.24M | 1.40B | 1.71B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 340.82M | 592.75M | 867.16M | 1.07B | 1.02B | 1.08B |
| Total Debt | 21.47M | 9.68M | 17.41M | 23.24M | 26.96M | 28.37M |
| Total Liabilities | 106.60M | 113.59M | 103.42M | 90.45M | 106.09M | 80.32M |
| Stockholders Equity | 317.33M | 557.62M | 885.82M | 1.31B | 1.61B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | -443.69M | -255.01M | -390.50M | -355.00M | -53.60M | -259.10M |
| Operating Cash Flow | -439.30M | -247.75M | -380.47M | -341.69M | -41.23M | -245.84M |
| Investing Cash Flow | 351.93M | 180.13M | 564.35M | 59.68M | -628.85M | -467.54M |
| Financing Cash Flow | -8.97M | -8.98M | -8.46M | 23.14M | 273.49M | 894.87M |
BioInvent International AB Technical Analysis
Positive
23.50
Price Trends
23.11
Positive
24.17
Negative
24.71
Negative
Market Momentum
0.01
Negative
53.46
Neutral
69.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Positive. The current price of 23.5 is above the 20-day moving average (MA) of 22.53, above the 50-day MA of 23.11, and below the 200-day MA of 24.71, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.46 is Neutral, neither overbought nor oversold. The STOCH value of 69.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BINV.
BioInvent International AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr386.26M | 2.01 | 63.09% | ― | ― | ― | |
53 Neutral | kr1.13B | -3.80 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr183.86M | -7.79 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr364.75M | -3.21 | -18.05% | ― | ― | 15.97% | |
43 Neutral | kr1.53B | -3.07 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr54.59M | -0.01 | -736.08% | ― | -98.81% | 80.33% |
* Healthcare Sector Average
SE:BINV
BioInvent International AB
23.20
-3.80
-14.07%
SE:ATORX
Alligator Bioscience AB
0.02
-0.85
-98.27%
SE:ONCO
Oncopeptides AB
2.96
-2.13
-41.83%
SE:ELIC
Elicera Therapeutics AB
2.76
-4.24
-60.61%
SE:IMMU
Immunicum AB
5.75
-0.16
-2.71%
SE:CANTA
Cantargia AB
1.37
-1.15
-45.63%
BioInvent International AB Corporate Events
BioInvent Balances Widening Losses With Strong Immuno-Oncology Milestones
Aug 27, 2026
BioInvent reported a sharp drop in net sales and a shift to a significant loss in the first half of 2026, with net sales falling to SEK 26.2 million from SEK 220.2 million and a loss after tax of SEK 242.1 million, while liquid funds more than hal...
BioInvent Publishes Key Preclinical Data on TNFR2 Antibodies BI-1808 and BI-1910
Aug 20, 2026
BioInvent International has announced the publication in Cancer Research of a peer-reviewed preclinical manuscript detailing the mechanism of action and broad antitumor efficacy of its anti-TNFR2 antibodies BI-1808 and BI-1910 across diverse tumor...
BioInvent Wins FDA Fast Track for BI-1808 in High-Need Ovarian Cancer
Aug 7, 2026
BioInvent has secured U.S. FDA Fast Track Designation for BI-1808, its first-in-class anti-TNFR2 antibody, in combination with pembrolizumab for the treatment of ovarian cancer, underscoring the company’s positioning as an emerging player in...
BioInvent Data Show FcγR-Targeting Antibodies Boost Checkpoint Therapy and Tackle Resistance
Jul 28, 2026
BioInvent International has reported new preclinical data in the Journal of Experimental Clinical Cancer Research showing that its FcγR-targeting antibodies BI-1206 and BI-1607 can enhance immune checkpoint therapies and overcome resistance ...
BioInvent’s BI-1808 Shows Promise in Tough Ovarian Cancer Setting
Jul 17, 2026
BioInvent International AB has reported progress with its first-in-class anti-TNFR2 antibody BI-1808, which has been accepted for poster presentation at the European Society for Medical Oncology Congress 2026 in Madrid. The abstract, titled “...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.